LBO — ST. CHARLES MED CTR-REDMOND
IRR: 16.3% | MOIC: 2.13x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
16.3%
IRR
2.13x
MOIC
$126.5M
Entry EV
$188.6M
Exit EV
$65.1M
Equity Invested
Sources & Uses
S&UTotal · $126.5M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $49.1M | 38.8% | |
| Sub Debt | $12.3M | 9.7% | |
| Equity | $65.1M | 51.5% | |
| Enterprise Value | $122.8M | 97.1% | |
| Transaction Fees | $3.7M | 2.9% | |
| Total Uses | $126.5M | 100.0% |
Interpretation
INTAt 2.13x MOIC and 16.3% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $18.0M |
| Exit Ev | $188.6M |
| Net Debt At Exit | $49.9M |
| Equity At Exit | $138.7M |
| Equity Invested | $65.1M |
| Total Value Created | $73.6M |
| Value From Growth | $59.6M |
| Value From Multiple | $6.1M |
| Value From Deleveraging | $11.5M |